SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.68-2.4%Dec 12 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: kenhott who wrote (14035)11/11/2004 10:13:36 PM
From: Biomaven  Read Replies (2) of 52153
 
points specifically at IIIb or IV

Not exactly:

From your link:

Official Title: Phase III Randomized Study of Polyglutamate Paclitaxel (CT-2103) and Carboplatin Versus Paclitaxel and Carboplatin in Patients With Stage IIIB or IV or Recurrent Non-Small Cell Lung Cancer Who Have a Performance Status of 2

(emphasis added).

Further in the eligibility requirements:

DISEASE CHARACTERISTICS:

* Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) meeting 1 of the following criteria:
* Locally advanced or recurrent disease previously treated with radiotherapy and/or surgery
* Stage IIIB and not a candidate for combined modality therapy
* Stage IV

So the way both my friend and I read it, you could have recurrent disease that was previously treated and be eligible even though you are not Stage IIB or IV.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News